The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Zacks Investment Research on MSN
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Vertex Pharmaceuticals (VRTX) announced that the FDA has granted breakthrough therapy designation to povetacicept for the treatment of IgAN. Pove ...
iPhone 17 goes on sale around the world: Huge queues form outside Apple Stores in Hong Kong, Sydney and Singapore - while a FIGHT breaks out at the Mumbai branch A video clip shows tempers boiling ...
The U.S. Food and Drug Administration approved twice-daily JOURNAVX for the treatment of adults with moderate-to-severe acute pain on January 30, 2025. JOURNAVX is a prescription medicine used to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback